EpiPen’s Dominance Driven By Competitors’ Stumbles And Tragic Deaths
NPR recently called on Petrie-Flom Academic Fellow alumnus Nicholson Price to help explain how Mylan's Epi-Pen has come to dominate the market for epinephrine autoinjectors. From the article:
The push to require EpiPens got a high-level boost in 2013, as President Obamadisclosed his daughter Malia's peanut allergy when he signed off on the federal law, which gives financial incentives to states that require the medication in schools. Co-author of the federal legislation, Rep. Steny Hoyer, D-Md., cited his 11-year-old granddaughter's peanut allergy when the EpiPen law passed the House. FARE and Mylan supported that as well.
With the help of these laws, Mylan's EpiPens are at 63,000 schools nationwide. The company also has distributed 500,000 of them for free through EpiPens4Schools.
The school giveaway program brings visibility and credibility to the EpiPen brand, building a consumer base beyond schools.
"It's kind of like the first hit's for free," says Nicholson Price, an assistant professor at the University of Michigan Law School. "You want to start people off with your product, and getting these products in at schools is a great way."
Check out the full article online.
And don't miss Price's take on the Epi-Pen controversy and what it tells us about pharmaceutical pricing over at Petrie-Flom's blog, Bill of Health!bioethics fda health care finance health law policy insurance market medical safety pharmaceuticals public health regulation w. nicholson price ii